IDH1 and acute myeloid leukemia: Baseline mutations in the RTK pathway genes (NRAS, KRAS, PTPN11, KIT, NF1, BRAF, or FLT3) were enriched in patients with mutant IDH1 AML who did not achieve disease remission with ivosidenib treatment [148].